
In elderly patients with chronic lymphocytic leukemia (CLL) taking obinutuzumab (Gazyva, Genentech), also known as GA101, in combination with chlorambucil lived nearly 1 year longer without worsening of their disease compared to rituximab in combination with chlorambucil, according to a study published online ahead of print in the New England Journal of Medicine.